The Future of Regulatory Processes in Cell and Gene Therapy Pharmaceutical Executive
Follow this link:
The Future of Regulatory Processes in Cell and Gene Therapy - Pharmaceutical Executive
JCR and Modalis Advance Joint Gene Therapy Research TipRanks
Excerpt from:
JCR and Modalis Advance Joint Gene Therapy Research - TipRanks
JCR Pharmaceuticals and Modalis Advance Joint Gene Therapy Research TipRanks
Read the rest here:
JCR Pharmaceuticals and Modalis Advance Joint Gene Therapy Research - TipRanks
Novartis Gene Therapy Shows Promise in Treating SMA Yahoo Finance
Continued here:
Novartis Gene Therapy Shows Promise in Treating SMA - Yahoo Finance
Gene Therapy Market to Hit Valuation of US$ 42.26 Billion By 2033 | Astute Analytica Yahoo Finance
Follow this link:
Gene Therapy Market to Hit Valuation of US$ 42.26 Billion By 2033 | Astute Analytica - Yahoo Finance
Novartis gene therapy helps children with rare muscle disorder in study Reuters
Read more from the original source:
Novartis gene therapy helps children with rare muscle disorder in study - Reuters
Capricor Puts Rolling BLA for DMD Cardiomyopathy Cell Therapy Deramiocel in Front of the FDA CGTLive
Go here to read the rest:
Capricor Puts Rolling BLA for DMD Cardiomyopathy Cell Therapy Deramiocel in Front of the FDA - CGTLive
Positive data could expand use of Novartis gene therapy for SMA Yahoo Finance
Follow this link:
Positive data could expand use of Novartis gene therapy for SMA - Yahoo Finance
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership MM+M Online
More:
Sangamo spirals after Pfizer halts hemophilia A gene therapy partnership - MM+M Online
Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model News & Insights
Originally posted here:
Struggling With Adoption, Sickle Cell Gene Therapy Manufacturers Embrace CMS Model - News & Insights
Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer Contract Pharma
See the original post here:
Sangamo Therapeutics to Regain Rights to Gene Therapy Program from Pfizer - Contract Pharma
All too often, when we see injustices, both great and small, we think, that's terrible, but we do nothing. We say nothing. We let other people fight their own battles. We remain silent because silence is easier. Qui tacet consentire videtur is Latin for 'Silence gives consent.' When we say nothing, when we do nothing, we are consenting to these trespasses against us.
Visit link:
Department of Genetic Medicine
The human genome contains about 20,000 protein coding genes distributed over 23 pairs of chromosomes (22 pairs of autosomes and the sex chromosomes, X and Y). Our genes provide the code of life..a blueprint for the processes that program every aspect of an individuals development from a single fertilized egg at the initiation of life to the trillions of cells that make up an adult.
Our genes also encode the mechanisms that maintain normal physiology in an ever-changing environment. The information within genes is determined by the linear sequence of four building blocks, G, A, T and C, which are called nucleotides. These components are arranged in long chain-like molecules that intertwine, forming a double helix that is about two meters in length. All of this is packaged into the nucleus of each of our cells, themselves thousands of times smaller than a raindrop.
Our genetic machinery is the product of more than a billion years of evolution. Understanding this marvelous feat of biology and how it functions in health and disease is a central goal for scientists in the Department of Genetic Medicineand requires a multi-faceted research program.
Johns Hopkins scientists have long been leaders in medical genetics research. The field essentially began in the 1950s with renowned scientist Victor McKusick, who is considered the father of medical genetics and led the world in identifying thousands of inherited diseases and mapping the responsible genes to specific locations on our chromosomes. Legendary geneticist Barton Childs is best known for his quest to get physicians to think about disease in the context of genetics. Nobel laureates Daniel Nathans and Hamilton Smith discovered molecular scissors called restriction enzymes, which revolutionized genetic research by providing a way to map our genome and isolate genetic material and insert it into DNA. These techniques, used continuously by laboratories across the world since Nathan and Smiths discoveries in the 1960s enabled molecular biology and was a precursor is to sequencing the human genome and to the recently identified, targeted gene-cutting tool, CRISPR/CAS9.
More on the history of the Departmentof Genetic Medicine
With innovations in genome sequencing over the last two decades, scientists have become very efficient at reading genetic material. Now, researchers are focusing on clinical applications of these advances including interpreting our genetic blueprints, relating these coded instructions to human disease and developing new ways to identify, treat and prevent disease.
The overarching goal of the Department of Genetic Medicineis to integrate genetics into all of medicine. In addition to genetic medicinescientists who study the fundamental links between our genes and disease, the Departmenthas a robust clinical service which operates seven patient clinics along with providing inpatient and outpatient services.
Thus, the Department of Genetic Medicineprovides a highly collaborative, innovative environment where scientists and physicians combine their knowledge to apply basic science discoveries to clinical care.
Facultyfocus on areas that include:
At the Departmentof Genetic Medicine, we take the power of research discoveries at Johns Hopkins and apply this knowledge to patients evaluated in our inpatient and outpatient clinics at The Johns Hopkins Hospital and its affiliates. As part of this effort, we haveexpandedthe size and scope of the services offered by Johns Hopkins Genomics, (JHG) one of the worlds largest centers for DNA genotyping and sequencing. JHG is a collaborative effort between the Departments of Genetic Medicineand Pathology to provide a variety of DNA genotyping and sequencing services, both research and clinical, to the patients, physicians and scientists of Johns Hopkins Medicine.
The Department of Genetic Medicinealso houses research centers with significant funding from the National Institutes of Health that provide services and resources for physicians and researchers at Johns Hopkins and around the world.
Thus, Department of Genetic Medicineresearchers and clinicians, work to move human genetics and its multi-faceted and expanding applications to medicine forward by providing a collaborative and dynamic culture of innovative research and clinical care.
Read more from the original source:
Research Services | Johns Hopkins Institute of Genetic Medicine
More than 2,000 people of all ages from across the globe seek information, diagnoses and ongoing care from experts at the McKusick-Nathans Institute of Genetic Medicine | Department of Genetic Medicine. The departmentis a hub of genetics knowledge and care that has moved medicine forward to bring decades of research advances to benefit human health. This is where the field of medical genetics was born and developed.
Johns Hopkins genetics experts are leaders and pioneers in their fields. They use the worlds most advanced technology, some of which was developed by our own scientific teams, to diagnose genetic conditions.
Our clinical team includes physicians, genetic counselors, dieticians, nurses, nurse practitioners and physician assistants who coordinate to develop accurate and timely diagnoses.
Our clinics specialize in unraveling the signs and symptoms of conditions to hone in on a diagnosis, whether the condition is extremely rare or more common. Your team is made up of the worlds experts in deciphering these clues to conditions and in managing your care.
Whether you are a newborn or in your retirement years, experts at our clinics will follow your care for life. Your lifelong link to experts at Johns Hopkins will help you stay informed on the latest advances in care for your condition. We also coordinate care with the Kennedy Krieger Institute, other medical centers and your local health care providers.
Our team will help you navigate the complex medical care that people with genetic conditions may need. We will make referrals and help to arrange appointments with specialists who have extensive knowledge and experience in treatments for people with genetic diseases. We work to get insurance coverage for genetic testing as well as additional needs, such as physical and speech therapy, and equipment, such as wheelchair and communication devices. We also help parents of students with genetic diseases work witheducators to meet their childs medical and learning needs.
Visit our COVID-19 resources page for information about what you can do to stay healthy.
See More
See the original post:
Patient Care | Johns Hopkins Department of Genetic Medicine
Like many medical facilities across the nation, our supply chain is feeling the effects of Hurricane Helenes aftermath. Johns Hopkins Medicine currently has a sufficient sterile fluid supply to meet treatment, surgical and emergency needs. However, we have put proactive conservation measures into place to ensure normal operations, always with patient safety as our first priority. Examples of sterile fluids include intravenous (IV), irrigation and dialysis fluids. Learn more.
More here:
Specialty Clinics | Johns Hopkins Institute of Genetic Medicine
Like many medical facilities across the nation, our supply chain is feeling the effects of Hurricane Helenes aftermath. Johns Hopkins Medicine currently has a sufficient sterile fluid supply to meet treatment, surgical and emergency needs. However, we have put proactive conservation measures into place to ensure normal operations, always with patient safety as our first priority. Examples of sterile fluids include intravenous (IV), irrigation and dialysis fluids. Learn more.
The rest is here:
Pediatric Genetic Medicine at Johns Hopkins Children's Center
The Department of Genetic Medicine maintains several large centers funded in part by the National Institutes of Health. These research resources have a long history at Johns Hopkins and provide the foundation for innovative research, as well as providing services and information to scientists around the world.
OMIM, is an encyclopedia of genetic disorders, their clinical features and the genes that contribute to them. The database contains information on thousands ofMendelian conditions, disorders caused by errors in a single gene. The database was developed 55years ago by Victor McKusick and is now maintained byAda Hamosh, MD, MPH, and her team. OMIM is used by 2.7 million unique users per year around the world.
GRCFprovides year-roundresearch expertise, products, and services for the study of the human genome. At the leading edge of technology, the GRCF provides sophisticated tools and equipment oftentimes not available in individual research labs. The mission of the GRCF is to provide high quality, cost effective research services and products to investigators throughout the Johns Hopkins scientific community. Accordingly, GRCF services cover a broad segment of genetic research including:
JHG provides research and clinical genotyping and sequencing together with extensive analytic expertise. A partnership between the Departments of Genetic Medicineand Pathology, JHG opened its doors in 2017, co-localizing four existing labs:
CIDR,is a national resource, offering sequencing, genotyping and epigenetic services to scientists looking to discover genes and variants that contribute to human disease. As part of Johns Hopkins Genomics, CIDR researchers focus on the genetic architecture of complex traits, looking at conditions that result from many genetic variants and how these variants accumulate to manifest disease. This includes conditions such as all types of cancer risk, eye diseases, cleft lip and palate, oral health, environmental influences on child health outcomes, ADHD, structural brain disorders, obesity, alcoholism and aging. Most recent studies are focused on minority populations or extremely well-phenotyped populations. CIDR facilitates data cleaning and data sharing. The 140 CIDR studies posted in dbGaP are heavily utilized with > 7,600 data requests. Since opening its doors in 1996, CIDR has been continuously funded by contracts from a consortium of ten National Institutes of Health institutes (the CIDR Program) as well as through funding from many other genomic consortia, including most recently the national precision medicine initiative, the All of Us Research Program. As of January 2024, CIDR has completed 1,508 studies, consisting of > 1.7 million DNA samples and encompassing over 200 different phenotypes for 421 principal investigators world-wide.
BHCMGaccepts samples from thousands of peoplewith rare disorders submitted by a worldwide network of rare-disease experts. A collaboration between Baylor College of Medicine and Johns Hopkins, the goal of the center is to sequence the genomes of people with these conditions as well as appropriate family members to identify the genes and variants responsible for disorders whose molecular basis was previously unknown. In particular, the center seeks families with known or novel conditions for which the culprit gene is unknown. Successful identification of the responsible gene connects a particular gene with a particular set of clinical features, thereby enabling precise molecular diagnosis and prognosis.It alsoinforms research on the development of rational treatment and providing families with information about recurrence risk.
Focused on Kabuki syndrome and related Mendelian disorders of the epigenetic machinery. These rare disorders result from mutations in single genes encoding components of the systems that add, interpret or delete epigenetic marks with the result that sets of genes are mis-regulated. Currently we know of more than 40 such epigenetic disorders, most of which have intellectual disability and growth abnormalities as prominent clinical consequences. By understanding the features and pathogenesis of these precise abnormalities of the epigenetic system IGM investigators expect to understand not only each disorder but also to how the whole epigenetic systems functions and the pathophysiological consequences that accrue when the system malfunctions. This research complements the clinical services offered in the IGM Epigenetics and Chromatin Clinic where patients with these disorders are diagnosed, characterized and treated.
Focused on understanding the molecular pathophysiology of the vascular form of Ehlers-Danlos syndrome (vascular EDS) with the aim of providing informed management of these patients as well as developing new forms of therapy. The Center will utilize advanced genetic and molecular methods to discover the sequence of events that contribute to structural weakening of the arterial wall and internal tissues over time, ultimately leading to tear or rupture and the potential for early death. The research team has developed two mouse models of vascular EDS that demonstrate most of the important physical findings seen in patients with the disorder. As in people with vascular EDS, we observe tremendous variation in the timing of onset and severity of vascular disease in our mouse colonies. Our strong belief is that both genetic and environmental factors have the capacity to afford strong protection in vascular EDS. Once identified, we will attempt to mimic the mechanism of protection using medications or other strategies. The Center also aims to coordinate expert clinical care of individuals with vascular EDS, and to promote research in the clinical sciences that will improve both the length and quality of life for affected individuals. The Center for Vascular Ehlers-Danlos Syndrome Research has received generous and visionary funding from a variety of sources including the EDS Network CARES Foundation, the EDS Today Advocates, the DEFY Foundation, the Aldredge Family Foundation, and the Daskal Family Foundation.
View post:
Research Centers | Johns Hopkins Institute of Genetic Medicine
The overall goal of the Department of Genetic Medicine is to integrate genetics into all of medicine. To this end, department of genetic medicine investigators are exploring the role of the genes and genetic variation in the generation of human phenotypes and using this knowledge in various ways to understand biology and to improve health.
The Department of Genetic Medicineclinical service is aimed at providing state-of-the-art care for our patients, as well as contributing to translational, patient-oriented research; providing a set of educational activities for our trainees; and importantly, serving as an exemplar of how genetics informs the care of individual patients. We recognize that for these activities to be successful we also must be active in the education of our students, our colleagues and the public at large.
The Department of Genetic Medicine has a committee on diversity, equity and inclusion. The committee's mission is to promote the personal and professional flourishing of individuals from all backgrounds, perspectives, and abilities. We seek to promote mutual respect and collaboration between individuals of diverse race, ethnicity, culture, physical characteristics, sex and gender identity, religion and nationality.
For Department members: read more on our Sharepoint Intranet site about committee members, events and initiatives.
See More
Continued here:
About Us - Johns Hopkins Medicine
Like many medical facilities across the nation, our supply chain is feeling the effects of Hurricane Helenes aftermath. Johns Hopkins Medicine currently has a sufficient sterile fluid supply to meet treatment, surgical and emergency needs. However, we have put proactive conservation measures into place to ensure normal operations, always with patient safety as our first priority. Examples of sterile fluids include intravenous (IV), irrigation and dialysis fluids. Learn more.
Here is the original post:
Graduate Programs & Training | Johns Hopkins Medicine